Literature DB >> 12657674

Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity.

Deanna L Taylor1, Lara T Diemel, Jennifer M Pocock.   

Abstract

A reduction in microglial activation and subsequent neurotoxicity may prove critical for neuroprotection in neurodegenerative diseases. We examined the expression and functionality of group III metabotropic glutamate (mGlu) receptors on microglia. Rat microglia express mRNA and receptor protein for group III mGlu receptors mGlu4, mGlu6, and mGlu8 but not mGlu7. Activation of these receptors on microglia with the specific group III agonists (L)-2-amino-4-phosphono-butyric acid (l-AP-4) or (R,S)-phosphonophenylglycine (RS-PPG) inhibited forskolin-induced cAMP production, linking these receptors to the negative inhibition of adenylate cyclase. These agonists did not induce a fall in mitochondrial membrane potential or apoptosis in the microglia, suggesting that activation of these receptors is not in itself toxic to microglia. Fluorescence-activated cell sorting analysis revealed that activation of group III mGlu receptors induces a mild activation of the microglia, as evidence by their enhanced staining with ED1. However, this activation is not neurotoxic. Agonists of group III mGlu receptors reduced microglial reactivity when they were activated with lipopolysaccharide (LPS), chromogranin A (CGA) or amyloid beta peptide 25-35 (Abeta25-35). Furthermore, l-AP-4 or RS-PPG treatment of microglia reduced their neurotoxicity after microglial stimulation with LPS or CGA but not Abeta25-35. Similar results were obtained with microglial conditioned medium or in coculture, suggesting that the activation of microglial group III mGlu receptors may modulate the production of stable neurotoxins from the microglia. These results suggest that selective modulation of microglial group III mGlu receptors may provide a therapeutic target in neuroinflammatory diseases such as Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657674      PMCID: PMC6742009     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  42 in total

Review 1.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors.

Authors:  D D Schoepp; D E Jane; J A Monn
Journal:  Neuropharmacology       Date:  1999-10       Impact factor: 5.250

2.  Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia.

Authors:  K Biber; D J Laurie; A Berthele; B Sommer; T R Tölle; P J Gebicke-Härter; D van Calker; H W Boddeke
Journal:  J Neurochem       Date:  1999-04       Impact factor: 5.372

3.  Molecular consequences of activated microglia in the brain: overactivation induces apoptosis.

Authors:  B Liu; K Wang; H M Gao; B Mandavilli; J Y Wang; J S Hong
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

4.  Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarisation and the permeability transition but not by cytochrome c release.

Authors:  P J Kingham; J M Pocock
Journal:  J Neurochem       Date:  2000-04       Impact factor: 5.372

5.  mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats.

Authors:  G P Schools; H K Kimelberg
Journal:  J Neurosci Res       Date:  1999-11-15       Impact factor: 4.164

6.  Apoptotic pathways mobilized in microglia and neurones as a consequence of chromogranin A-induced microglial activation.

Authors:  P J Kingham; M L Cuzner; J M Pocock
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

7.  (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.

Authors:  F Gasparini; V Bruno; G Battaglia; S Lukic; T Leonhardt; W Inderbitzin; D Laurie; B Sommer; M A Varney; S D Hess; E C Johnson; R Kuhn; S Urwyler; D Sauer; C Portet; M Schmutz; F Nicoletti; P J Flor
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

8.  Temporal analysis of growth factor mRNA expression in myelinating rat brain aggregate cultures: increments in CNTF, FGF-2, IGF-I, and PDGF-AA mRNA are induced by antibody-mediated demyelination.

Authors:  C A Copelman; M L Cuzner; N Groome; L T Diemel
Journal:  Glia       Date:  2000-06       Impact factor: 7.452

9.  The metabotropic glutamate system promotes neuronal survival through distinct pathways of programmed cell death.

Authors:  A M Vincent; K Maiese
Journal:  Exp Neurol       Date:  2000-11       Impact factor: 5.330

Review 10.  Molecular determinants of metabotropic glutamate receptor signaling.

Authors:  A De Blasi; P J Conn; J Pin; F Nicoletti
Journal:  Trends Pharmacol Sci       Date:  2001-03       Impact factor: 14.819

View more
  53 in total

1.  Metabotropic glutamate receptor-mediated signaling in neuroglia.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-11

2.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Matthew J Betts; Michael J O'Neill; Susan Duty
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 3.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

4.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia.

Authors:  Ranjani Ponnazhagan; Ashley S Harms; Aaron D Thome; Asta Jurkuvenaite; Rocco Gogliotti; Colleen M Niswender; P Jeffrey Conn; David G Standaert
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

Review 6.  Microglia.

Authors:  Denise van Rossum; Uwe-Karsten Hanisch
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 7.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

9.  Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity.

Authors:  Kimberly R Byrnes; Bogdan Stoica; David J Loane; Angela Riccio; Margaret I Davis; Alan I Faden
Journal:  Glia       Date:  2009-04-01       Impact factor: 7.452

Review 10.  The role of glutamate and the immune system in organophosphate-induced CNS damage.

Authors:  Arik Eisenkraft; Avshalom Falk; Arseny Finkelstein
Journal:  Neurotox Res       Date:  2013-03-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.